1. Introduction {#sec1}
===============

Chronic pain is a medical condition that is often refractory to currently available pharmacotherapy. In particular neuropathic pain is resistant to the majority of conventional analgesics, and drugs that are effective carry a high rate of side-effects. The identification of novel drug targets based on disease mechanisms and the development of new analgesic drugs targeting the biological processes that underlie pain offer the opportunity to improve the current situation.

Many chronic pain states are accompanied by diminished synaptic inhibition at the spinal cord level ([@bib5], [@bib30], [@bib33], [@bib40]). Conversely, pharmacological enhancement of GABAergic inhibition in the spinal cord through locally applied DZP reverses pathologically increased pain sensitivity (hyperalgesia) in rodent models of chronic inflammatory and neuropathic pain ([@bib15]). The generation of GABA~A~R point-mutated ("knock-in") mice which carry a histidine to arginine (H → R) point mutation rendering the mutated GABA~A~Rs insensitive to DZP (and many other BDZ site agonists) has allowed attributing different *in vivo* actions of BDZ to different subtypes GABA~A~Rs ([@bib21]). Analysis of these mice in different pain models indicated that antihyperalgesic actions of BDZ occur mainly through spinal α2GABA~A~Rs ([@bib15], [@bib26]). Genetically modified (triple GABA~A~ receptor point-mutated) mice, in which only one GABA~A~R subtype was left BDZ-sensitive, demonstrated that pronounced antihyperalgesia can be achieved with systemic DZP administration without signs of sedation or impaired motor coordination when only α2GABA~A~Rs are targeted ([@bib28]). Conversely, many of the typical side effects of classical BDZ such as sedation, addiction, and motor impairment depend on activation of α1GABA~A~Rs ([@bib28], [@bib31], [@bib35]). The observation that desired and unwanted effects of classical BDZ site agonists are mediated by distinct GABA~A~R subtypes has stimulated the development of new compounds with improved subtype selectivity ([@bib32]). Such compounds were also evaluated in different preclinical pain models ([@bib8], [@bib13], [@bib15], [@bib16], [@bib23], [@bib25], [@bib26], [@bib29], reviewed in [@bib40]) and provided proof-of-concept evidence that the results obtained in genetically modified mice translate into *in vivo* antihyperalgesic efficacy of novel BDZ site agonists with improved subtype selectivity.

However, in the light of recent concerns raised about the predictive value of animal and, in particular, rodent models in pain research ([@bib36]), it appears important to obtain proof-of-concept data on the translatability of these findings to humans. Classical BDZ site agonists such as clonazepam and CBZ exert weak analgesic effects when given at standard therapeutic doses ([@bib4], [@bib38]). Our recent preclinical study ([@bib28]) that compared antihyperalgesic and sedative effects of DZP in genetically modified mice suggests that the doses needed to achieve relevant analgesia can typically not be achieved in human patients because of dose limiting sedation. Compounds devoid of α1GABA~A~R-mediated sedation should circumvent this problem. However, none of the currently available compounds with improved α2GABA~A~R selectivity have so far been approved for use in humans. We therefore evaluated alternative possibilities for proof-of-concept studies in humans. In a previous preclinical pharmacokinetic/pharmacodynamic (PK/PD) study on possible antihyperalgesic effects of CBZ we found that antihyperalgesic effects correlated better with blood levels of the main metabolite *N*-desmethyl clobazam (NDMC) than with blood levels of the parent compound CBZ ([@bib3]). In the present study, we have systematically evaluated the subtype selectivity of NDMC in recombinant GABA~A~Rs, its antihyperalgesic effects in a mouse model of neuropathic pain and its propensity towards sedation. We found that NDMC has a better α2/α1-GABA~A~R selectivity-profile than the parent compound CBZ and better than the canonical BDZ site agonist DZP. This more favorable *in vitro* profile translated to profound antihyperalgesic activity at doses that caused no or only mild sedation. Because NDMC is a naturally occurring metabolite of CBZ in humans ([@bib9]) and has already been given in-first-in-man clinical studies targeting patients with treatment refractory epilepsy ([@bib10]), NDMC could constitute a suitable tool compound for proof-of-concept studies exploring its antihyperalgesic potency in chronic pain conditions in humans.

2. Materials and methods {#sec2}
========================

2.1. Drugs {#sec2.1}
----------

DZP and CBZ were obtained from Lipomed AG, Arlesheim, Switzerland. NDMC was obtained from Imaginechem Co, Ltd, Hangzhou, China. NDMC was tested for purity, which was 99%.

2.2. Mice {#sec2.2}
---------

Experiments were performed in two strains of wild-type mice (C57BL/6J and 129X1/SvJ), and in homozygous triple and quadruple (H → R) GABA~A~R point-mutated mice of the 129X1/SvJ background ([@bib28]). Triple and quadruple point-mutated mice were generated by cross-breeding of four strains of single point-mutated mice described previously ([@bib6], [@bib18], [@bib31]).

2.3. \[^3^H\]flunitrazepam binding to transfected HEK293 cells {#sec2.3}
--------------------------------------------------------------

HEK293 cells (ATCC) were maintained in DMEM/10% FBS and plated to a density of 800,000 cells onto 10 cm culture dishes 3 h before transfection with plasmids containing the rat subunits α1, β2 and γ2 or α2, β3 and γ2 (8 μg total DNA/culture dish, ratio 1:1:2) using the PEI transfection method. Forty-eight hours after transfection, HEK293 cells were harvested in PBS for \[^3^H\]flunitrazepam binding. HEK 293 cells were homogenized in 20 vol 50 mM Tris pH 7.5, protease inhibitor cocktail (complete Mini, Roche Applied Science) and centrifuged at 500 g for 10 min at 4 °C. To obtain the crude membrane fraction, the supernatants were centrifuged for 20 min at 100,000 g (4 °C). The crude membranes were washed 4 times in 5 mM Tris-HCl pH 7.4, 10 mM EDTA by resuspension and centrifugation and stored at −80 °C until used. Crude membranes were then washed once in 50 mM Tris pH 7.5 (containing protease inhibitor cocktail) and aliquots (∼100 μg protein) were incubated with increasing concentrations of DZP, CBZ or NDMC and 1 nM \[^3^H\]flunitrazepam (79.8 Ci/mmol, PerkinElmer) in a total volume of 200 μl for 120 min on ice. Subsequently, the samples were filtered onto glass fiber filters using a 12-channel semiautomated cell harvester (Scatron) and washed with ice-cold buffer (50 mM Tris-HCl pH 7.4). Non-specific \[^3^H\]flunitrazepam binding was determined using 10 μM flumazenil. The radioactivity retained by the filters was determined by liquid scintillation counting using a Tricarb 2500 liquid scintillation analyzer. Binding data were analyzed using the GraphPad Prism software (version 5.04, GraphPad Software, USA).

2.4. Electrophysiology {#sec2.4}
----------------------

The effects of DZP, CBZ and NDMC on currents through recombinant GABA~A~Rs were studied in HEK293 cells transiently transfected with rat GABA~A~R subunits using lipofectamine LTX 46 (Invitrogen). To ensure expression of the γ2 subunit (required for modulation of GABA~A~R currents by BDZs) in all recorded cells, we transfected cells with a plasmid expressing the γ2 subunit plus eGFP from an IRES, and selected only eGFP-positive cells for recordings (see also [@bib28]). The transfection mixture contained (in μg): 1 αx, 1 βy, 3 γ2/eGFP. Whole-cell patch-clamp recordings were made at room temperature (20--24 °C) at a holding potential of -60 mV 18--36 h after transfection 60. Recording electrodes were filled with solution containing (in mM): 120 CsCl, 10 EGTA, 10 HEPES (pH 7.40), 4 MgCl~2~, 0.5 GTP and 2 ATP. The external solution contained (in mM): 150 NaCl, 10 KCl, 2.0 CaCl~2~, 1.0 MgCl~2~, 10 HEPES (pH 7.40), and 10 glucose. GABA was applied to the recorded cell using a manually controlled pulse (6--10 s) of a low sub-saturating GABA concentration (EC~10~). EC~10~ values of GABA were 1 μM, 5 μM, 8 μM, and 1 μM for the four GABA~A~R combinations (α1β2γ2, α2β3γ2, α3β3γ2 and α5β2γ2), respectively. EC~50~ values and Hill coefficients (n~H~) were obtained from fits of normalized concentration-response curves to the Hill equation I~GABA~ = I~max~ \[GABA\]^nH^/(\[GABA\]^nH^ + \[EC~50~\]^nH^). I~max~ was determined as the average maximal current elicited by saturating concentration of GABA (30 μM--3 mM, depending on the subunit composition). DZP, CBZ and NDMC were dissolved in DMSO (final concentration \< 0.1%) and subsequently diluted on the day of the experiment in external solution and were co-applied with GABA without preincubation. Concentration-response curves of the three BDZ were fitted to the Hill equation: E(C) = (E~max~·\[C\]^nH^)/(\[C\]^nH^ + \[EC~50~\]^nH^).

2.5. Quantitative RT-PCR {#sec2.5}
------------------------

Twelve lumbar spinal cords and hippocampi were rapidly removed from euthanized adult wild-type C57BL/6 and 129X1/SvJ mice. mRNA was transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen no. 205311). Expression of GABA~A~R subunits was assessed using β-actin as reference gene.

2.6. Animal experiments {#sec2.6}
-----------------------

All behavioral experiments were performed in 7--10 week old female and male mice by an experimenter blinded to the genotype or treatment of the mice. Care was taken to ensure equal numbers of female and male mice in all groups. Permission for animal experiments was obtained from the Veterinäramt des Kantons Zürich (license numbers 135/2009 and 126/2012). For behavioral experiments, DZP, CBZ and NDMC were suspended in 0.9% saline, 1% Tween80 and applied orally (p.o.) in all experiments.

Neuropathic pain was evoked by applying a chronic constriction injury (CCI; [@bib41]) to the left sciatic nerve proximal to the trifurcation with three loose (5-0 silk) ligatures. Mice which showed signs of paralysis were excluded from subsequent experiments. Effects of DZP and NDMC on thermal and mechanical hyperalgesia were assessed between 7 and 14 days after surgery. Heat hyperalgesia was quantified as the change in the latency of paw withdrawal evoked by exposure of the plantar side of one hindpaw to a defined radiant heat stimulus (Hargreaves test). Mechanical hyperalgesia was assessed with an electronic von Frey apparatus using filament \#7 (IITC, Woodland Hills, CA). Three to four measurements were made for each time point and animal for both heat and mechanical hyperalgesia. Percent maximal possible effects (%MPE) were calculated as follows:

%MPE(t) = 100 \* (E(t) − E~predrug~))/(E~preCCI~ − E~predrug~); E(t), paw withdrawal thresholds or latency at time point t. E~predrug~, E after CCI surgery but before DZP application; E~preCCI~, E baseline before CCI surgery.

Locomotor activity was measured in an open field arena (20 cm diameter) equipped with four pairs of light beams and photosensors. Drugs were administered immediately before placing the animal into the recording chamber. Locomotor activity was analyzed for the time interval between 72 and 120 min after drug administration.

2.7. NDMC pharmacokinetics {#sec2.7}
--------------------------

NDMC blood concentrations were evaluated after at various time points after oral administration of 3, 10 and 30 mg kg^−1^, using the dried blood spot sampling method ([@bib7]). This technique allows collecting multiple bleeds from the same animal over a large time window. Four μl of whole blood were collected and spotted onto a filter paper card from Whatman (Dassel, Germany) at different time points between 0 and 48 h after NDMC administration. NDMC blood and brain tissue concentration were in addition determined at 2 h after a single oral dose of 1, 3, 10, 30, and 100 mg kg^−1^. NDMC concentration measurements were performed using a fully validated LC-MS-MS method ([@bib3]). Pharmacokinetic parameters were estimated using a non-compartmental method using WinNonlin^®^ version 5.2 (Pharsight, Mountainview, CA, USA).

3. Results {#sec3}
==========

3.1. GABA~A~R subtype selectivity {#sec3.1}
---------------------------------

We first analyzed the effect of DZP, CBZ and NDMC as positive allosteric modulators of recombinant GABA~A~Rs expressed in HEK293 cells ([Fig. 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}, for chemical structures see [Fig. 1](#fig1){ref-type="fig"}A). In electrophysiological experiments, all three compounds potentiated currents through α1β2γ2, α2β3γ2, α3β3γ2 and α5β2γ2 GABA~A~Rs (short α1-, α2-, α3- and α5GABA~A~Rs) but did not directly activate GABA~A~R currents at the concentrations tested (up to 3 μM for DZP, and 20 μM for CBZ and NDMC). Differences were observed with respect to the potency and efficacy of the three compounds at the four GABA~A~R subtypes. DZP potentiated currents through all four subtypes with EC~50~ values between 0.029 and 0.071 μM. CBZ and NDMC were less potent with EC~50~ values between 0.39 and 1.1 μM and between 0.49 and 0.81 μM, respectively ([Table 1](#tbl1){ref-type="table"}). Pronounced differences were found when comparing the efficacy of potentiation by the three compounds at the different GABA~A~R subtypes. Potentiation by DZP was strongest for α3GABA~A~Rs (237%), while potentiation of the other three GABA~A~R subtypes ranged between 100% and 141%. At concentrations \< EC~50~, which are probably more relevant to therapeutic effects of DZP, α1GABA~A~Rs were potentiated more strongly than α2-, α3- and α5GABA~A~Rs ([Fig. 1](#fig1){ref-type="fig"}B). CBZ and DZP had very similar efficacies at the four GABA~A~R subtypes, but CBZ differentiated less between subtypes at sub-saturating concentrations ([Fig. 1](#fig1){ref-type="fig"}C). NDMC potentiated α2 and α3GABA~A~Rs to a considerably higher degree (253 and 245%) than α1 and α5 (143 and 148%) ([Fig. 1](#fig1){ref-type="fig"}D). Taken together, DZP preferred α1GABA~A~Rs at low concentrations and α3GABA~A~Rs at high concentrations. CBZ was rather non-specific at low concentrations and preferred α3GABA~A~Rs at high concentrations. NDMC showed the strongest potentiation at α2GABA~A~Rs over the concentration range tested. We also determined relative affinities of the three compounds to the α1 and α2GABA~A~Rs. DZP bound both receptors with more than ten-fold higher affinities than CBZ and NDMC, but differences in affinity between the GABA~A~R subtypes were generally low ([Table 1](#tbl1){ref-type="table"}).

3.2. Antihyperalgesic actions {#sec3.2}
-----------------------------

The previous study by [@bib3]) has demonstrated antihyperalgesic effects of systemically applied CBZ in mice. Pharmacokinetic/pharmacodynamic modeling has suggested that most of the antihyperalgesia observed in mice following CBZ administration originated from the CBZ metabolite NDMC. We therefore assessed antihyperalgesic actions of NDMC using the chronic constriction injury (CCI) model of neuropathic pain. Following CCI surgery, all mice developed pronounced mechanical and heat hyperalgesia. Seven to 14 days after surgery, mice were treated systemically (p.o.) with three different doses of NDMC (3, 10, or 30 mg kg^−1^) or with vehicle. NDMC dose-dependently reduced both heat and mechanical hyperalgesia. No significant differences were observed between results obtained in mice of the 129X1/SvJ background, the genetic background of the GABA~A~R point-mutated mice used in this study ([Fig. 2](#fig2){ref-type="fig"}A,B), and in C57BL/6J mice the mouse strain most frequently used in the preclinical pain studies ([Fig. 2](#fig2){ref-type="fig"}C,D). To ensure that NDMC induced antihyperalgesia through the high-affinity BDZ binding site located at the interface between an α subunit and the γ subunit, we made use of quadruple point-mutated mice that carry the H → R mutation in the α1, α2, α3, and α5 subunits, i.e. in all α subunits that can form high affinity BDZ binding sites. In these quadruple point-mutated mice, NDMC (30 mg kg^−1^) had completely lost its antihyperalgesic effects ([Fig. 2](#fig2){ref-type="fig"}E,F).

3.3. Sedation {#sec3.3}
-------------

The more favorable α2/α1 selectivity profile of NDMC found in our *in vitro* experiments should manifest in a reduced propensity to sedation at doses with equipotent antihyperalgesic activity. We therefore compared the effects of DZP and NDMC (3, 10, and 30 mg kg^−1^ body weight) on locomotor activity in the open field test ([Fig. 3](#fig3){ref-type="fig"}). We performed these tests again both in C57BL/6J ([Fig. 3](#fig3){ref-type="fig"}A,B) and 129X1/SvJ mice ([Fig. 3](#fig3){ref-type="fig"}C,D) and monitored locomotor activity for 6 h after drug application. Statistical analyses were made for the time period between 72 and 120 min, which was the time interval of maximal drug effect in the pain tests described below. In C57BL/6J mice, DZP induced a dose-dependent reduction in locomotor activity, which reached statistical significance already at a dose of 1 mg kg^−1^ ([Fig. 3](#fig3){ref-type="fig"}A). In the same mouse strain, NDMC reduced locomotor activity only slightly and only at the highest dose tested (30 mg kg^−1^) ([Fig. 3](#fig3){ref-type="fig"}B). Reduction in locomotor activity was less pronounced in 129X1/SvJ mice ([Fig. 3](#fig3){ref-type="fig"}C,D). In these mice, NDMC did not reduce locomotor activity at any of the doses tested, while reduction in locomotor activity by DZP reached significance only at doses ≥10 mg kg^−1^.

Although reduced sedative effects were expected from the more favorable α2/α1 activity ratio of NDMC, the almost complete lack of sedation was surprising, since NDMC still potentiated α1GABA~A~Rs with an efficacy similar to DZP (compare [Fig. 1](#fig1){ref-type="fig"}). We therefore tested whether NDMC evoked sedation in triple (H → R) GABA~A~R point-mutated (129X1/SvJ) mice in which only the α1GABA~A~Rs retained a high affinity BDZ binding site ([@bib28]). For brevity, we refer to these mice as HRRR and to mice in which only α2GABA~A~Rs retained their high affinity BDZ binding site as RHRR mice. As a pre-requisite of these experiments, we verified that recombinant GABA~A~Rs harboring point-mutated α subunits lose their modulation by NDMC ([Fig. S1](#appsec1){ref-type="sec"}). When locomotor sedating effects of DZP and NDMC were tested in HRRR mice, both compounds exerted pronounced sedative effects. At antihyperalgesic doses (3--10 mg kg^−1^), locomotor activity was completely suppressed by DZP, while, in case of NDMC, strong (\>50%) suppression of locomotor activity became apparent at doses of 10 and 30 mg kg^−1^ ([Fig. 4](#fig4){ref-type="fig"}A,B). Restricting the action of a BDZ site agonist to α1GABA~A~Rs thus appears to render mice more susceptible to locomotor sedation. The presence of a motor sedative effect by NDMC in HRRR mice but not in wild-type mice may suggest that α2GABA~A~R-mediated stimulation of locomotion ([@bib28]) occludes locomotor sedating actions of α1GABA~A~Rs. We therefore tested NDMC's and DZP's effects on locomotor activity also in RHRR mice. Both compounds indeed increased locomotion in RHRR mice ([Fig. 4](#fig4){ref-type="fig"}C,D). It is therefore likely that this locomotor stimulant effect is related to the anxiolytic action of α2GABA~A~R activation ([@bib18]).

In this context, it was interesting to see that wild-type mice of the 129X1/SvJ genetic background were less susceptible to the motor sedating actions of DZP and NDMC than C57BL/6 mice. A previous study reported that GABA~A~R subunit expression levels vary between mice of different genetic backgrounds and that expression of *gabra2*, the gene encoding for the GABA~A~Rs α2 subunit is unusually low in C57BL/6 mice ([@bib22]). We therefore compared its expression levels in spinal cords and hippocampi in the two mouse strains using qRT-PCR. The α2 subunit expression was higher in 129X1/SvJ than in C57BL/6 mice by factors of 3.5 ± 0.03 (unpaired *t*-test, *P* \< 0.001, n = 12 for both strains) and 4.1 ± 0.04 (*P* \< 0.001, n = 12 for both strains) for spinal cord and hippocampus, respectively. We also found differences in α5 subunit expression, which was higher in C57BL/6 than in 129X1/SvJ mice by factors of 2.8 ± 0.6 (spinal cord, n = 12 for both genotypes) and 2.2 ± 0.4 (hippocampus, *P* \< 0.01, n = 9 and 12 for C57BL/6 and 129X1/SvJ). No significant differences were found between the other subunits contributing to the high affinity BDZ binding sites (α1, α3, and γ2) ([Fig. S2](#appsec1){ref-type="sec"}).

To address whether a low affinity BDZ binding site could be involved in NDMC-induced sedation, we analyzed also the motor sedative effects in the quadruple point-mutated RRRR mice ([Fig. 4](#fig4){ref-type="fig"}E,F). NDMC left locomotor activity unchanged at doses up to 100 mg kg^−1^ ([Fig. 4](#fig4){ref-type="fig"}F), which is 10-fold higher than the dose required for half-maximal antihyperalgesia. By contrast, at high doses (≥30 mg kg^−1^) of DZP reduced locomotor activity also in these mice ([Fig. 5](#fig5){ref-type="fig"}E). This observation is in line with our previous study ([@bib28]). It is likely that this remaining sedation occurs through the low affinity-binding site in the transmembrane domain described by [@bib39].

3.4. Pharmacokinetics of NDMC {#sec3.4}
-----------------------------

In order to relate the results of our behavioral *in vivo* experiments to the NDMC activity profiles measured *in vitro*, we determined pharmacokinetic parameters of NDMC in C57BL/6 mice after systemic (p.o.) administration ([Fig. 5](#fig5){ref-type="fig"}A and [Table 2](#tbl2){ref-type="table"}). Whole blood NDMC concentrations were measured with LC-MS-MS following single oral doses of 3, 10 and 30 mg kg^−1^ in three mice per group. Maximal blood levels were reached within 2--3 h. Average maximum blood concentrations were 4.1, 6.6, and 11.5 μM and half-life was between 4.6 and 5.6 h ([Fig. 5](#fig5){ref-type="fig"}A). We also compared whole blood and brain tissue concentrations reached 2 h after p.o. administration of 1--100 mg kg^−1^ NDMC in 129X1/SvJ mice ([Fig. 5](#fig5){ref-type="fig"}B). Average maximum whole blood concentrations ranged from 1.0 μM (after 1 mg kg^−1^) to 20.6 μM (after 100 mg kg^−1^). Brain concentrations determined at the same time point were between 3.4 and 4.0 times higher than whole blood concentrations.

3.5. Therapeutic windows of DZP and NDMC {#sec3.5}
----------------------------------------

We have previously suggested that one of the major reasons limiting the analgesic efficacy of DZP and other non-selective BDZ in clinical practice is dose-limiting sedation, i.e. sedation already occurs at doses much lower than those necessary for antihyperalgesia ([@bib28]). Classical BDZs hence lack a therapeutic window for antihyperalgesia. The present study suggests that NDMC has a better α2/α1 selectivity profile than DZP, and might thus have a more favorable therapeutic window. We therefore compared the dose dependencies of DZP- and NDMC-induced sedation and antihyperalgesia, assessed as reduced responses to von-Frey filament stimulation ([Fig. 6](#fig6){ref-type="fig"}). To avoid confounding effects of anxiolysis in sedation experiments and of sedation on antihyperalgesia, we assessed sedation in triple (H → R) point-mutated mice, in which all GABA~A~Rs except α1 had been rendered BDZ-insensitive. Conversely, antihyperalgesia was studied in GABA~A~R α1(H → R) point-mutated mice to rule out confounding sedation. In case of DZP, dose response curves showed the expected difference in ED~50~ values with sedation occurring at 6-7-fold lower doses (0.59 ± 0.08 mg kg^−1^) than antihyperalgesia (3.4 ± 1.3 mg kg^−1^). By contrast, NDMC exerted antihyperalgesia and sedation with similar ED~50~ values (3.4 ± 0.8 mg kg^−1^ and 3.1 ± 0.9 mg kg^−1^ for sedation and antihyperalgesia, respectively).

4. Discussion {#sec4}
=============

The present study suggests that NDMC might be a suitable compound for human proof-of-concept trials assessing a potential antihyperalgesic efficacy of BDZ site agonists with improved subtype selectivity in chronic neuropathic pain patients. This conclusion is based on three observations. (1) In recombinant receptors, NDMC had a more favorable α2- over α1GABA~A~Rs activity ratio than its parent compound CBZ and than the classical BDZ agonist DZP. (2) Unlike DZP, NDMC caused either no or only modest sedation at antihyperalgesic doses in two strains of wild-type mice. (3) Even under conditions, which unmasked sedative effects of NDMC (i.e. in the triple point-mutated mice), the therapeutic window of NDMC was significantly better than that of DZP.

*In vitro*, saturating concentrations of DZP and CBZ potentiated both GABA~A~R subtypes with similar efficacy, while NDMC clearly favored α2- over α1GABA~A~Rs. At low concentrations (\<EC~50~), NDMC preferred α2GABA~A~Rs across the entire concentration range tested, while CBZ had about similar effects on α2- and α1GABA~A~Rs and DZP favored α1GABA~A~Rs. This result is largely consistent with a previous report on the efficacy of CBZ and NDMC at GABA~A~R subtypes expressed in *Xenopus laevis* oocytes ([@bib11]). That study also found an improved α2/α1 selectivity ratio for NDMC of 1.33 ± 0.06 (versus 1.02 ± 0.05 for CBZ) in human GABA~A~Rs. The more favorable α2/α1 selectivity ratio very likely underlies the better therapeutic window of NDMC compared to DZP. Our pharmacokinetic analyses revealed that average peak whole blood concentrations after analgesic doses ranged between 4.2 µM (after 3 mg kg^−1^) and 11.5 μM (after 30 mg kg^−1^). These concentrations are remarkably similar to blood levels reported for human patients during chronic treatment with antiepileptic doses of NDMC (1000--3000 ng ml^−1^, equivalent to 3.5--10.5 μM; [@bib10]). Assuming a cerebrospinal fluid (CSF)/serum concentration ratio of about 0.1 ([@bib17]) and a serum/whole blood ratio of 1.7 (similar to that of DZP, [@bib14]), the blood levels measured in this study correspond to roughly 0.7--2 μM NDMC in the CSF. Thus, the drug concentrations relevant for the *in vivo* analgesic effects of NDMC are above the *in vitro* EC~50~ values at GABA~A~Rs. Accordingly, differences in the *in vitro* efficacy at concentrations above rather than below EC~50~ appear to determine the i*n vivo* pharmacological profile of NDMC.

While no or only very weak sedation was observed in wild-type mice after NDMC administration, locomotor sedation became apparent when the action of NDMC was restricted to α1GABA~A~Rs, i.e. in α2/α3/α5 (HRRR) triple point-mutated mice. This result was not unexpected because all three compounds tested exhibited similar efficacy at α1GABA~A~Rs. Nevertheless, even when analyzed under these conditions, the therapeutic window of NDMC was greatly improved compared to that of DZP.

In the present study, we did not include CBZ in the *in vivo* experiments, because, in mice, CBZ is very rapidly metabolized into NDMC. Already 15 min after administration of CBZ, blood levels of NDMC exceed those of CBZ ([@bib3]) suggesting that NDMC would make a major contribution to any *in vivo* effect seen after CBZ administration. In humans, this conversion occurs much more slowly with blood concentrations of CBZ exceeding those of NDMC for more than 24 h after a single oral dose of 20 or 30 mg CBZ ([@bib4], [@bib27]). It is hence likely that, in humans, treatment with NDMC -- instead of with the parent compound CBZ -- would improve the therapeutic margin and result in less sedation at concentrations where antihyperalgesia is expected. On the other hand, after prolonged treatment of humans steady-state NDMC concentrations exceed those of CBZ by a factor of 2.6--3.8 ([@bib37]). This may contribute to the relatively (compared to DZP) low propensity of CBZ to cause sedation during chronic treatment ([@bib20], [@bib34]). In this context, it might be worth noting that the improved α2/α1 selectivity ratio may not only contribute to a reduced propensity to sedation but may also be relevant for other possible indications such as autism spectrum disorders where activity at non-α1GABA~A~Rs improves social interactions ([@bib12], [@bib24]).

Drug discovery and development programs have yielded BDZ site agonists with negligible activity at α1GABA~A~Rs such as L-838,417 ([@bib19]), TPA023 ([@bib2]), and TPA023B ([@bib1]). While the lack of efficacy at α1GABA~A~Rs avoids unwanted sedative and other undesired effects, a possible limitation of these compounds is their only partial agonistic activity at α2GABA~A~Rs. L-838,417 potentiates recombinant α2β3γ2 GABA~A~Rs only by about 40% ([@bib19]), and potentiation of recombinant α2β3γ2 GABA~A~Rs by TPA023 and TPA023B reached only 11% and 38% of that of chlordiazepoxide ([@bib2], [@bib1]). By contrast, NDMC exhibited even stronger efficacy at α2GABA~A~Rs than the full agonist DZP. A correlation of α2GABA~A~R occupancy and antihyperalgesic effects performed for DZP indicates that significant analgesia (\>50% maximum possible effect) is only achieved at about 70% receptor occupancy even when a full agonist is used ([@bib28]). This may indicate limited antihyperalgesic efficacy of subtype selective agonists with only partial agonistic activity at α2GABA~A~Rs. Compared to these compounds, NDMC has a less favorable selectivity ratio but much higher activity at α2GABA~A~Rs. It remains to be seen whether the α1GABA~A~R activity of NDMC at antihyperalgesic doses is still a critical limitation.

In summary, our study demonstrates that NDMC possesses not only an improved α2/α1 GABA~A~Rs activity ratio *in vitro*, but also a more favorable *in vivo* pharmacological profile than classical BDZ. While DZP induced half-maximal sedation at doses much lower than those required for antihyperalgesia, NDMC elicited both actions with similar dose-dependencies. Since NDMC is a naturally occurring metabolite of CBZ ([@bib9]), its safety profile is already known from its parent drug CBZ and it is very unlikely that unexpected adverse effects emerge. NDMC might thus constitute a useful and safe compound for investigator initiated proof-of-concept trials in human volunteers or pain patients.
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![Potentiating effects of DZP, CBZ and NDMC on the four BDZ-sensitive GABA~A~R subtypes. (A) Chemical structure of DZP, CBZ, and NDMC. (B--D) GABA-evoked membrane currents were measured in HEK293 cells transiently transfected with recombinant α1β2γ2, α2β3γ2, α3β3γ2, and α5β2γ2 GABA~A~Rs. Top panels, traces show current responses evoked by GABA before and during application of a saturating concentration of DZP, CBZ, or NDMC (1 μM in case of DZP, and 20 μM in case of CBZ and NDMC). Light and dark traces were recorded before and during application of the BDZ, respectively. GABA was applied at EC~10~ in all experiments (1 μM, 5 μM, 8 μM, and 1 μM, for α1β2γ2, α2β3γ2, α3β3γ2, and α5β2γ2 GABA~A~Rs, respectively) for 6--10 s. Scale bars, 2 s and 200 pA. Bottom panels, concentration response curves of DZP, CBZ and NDMC obtained for the four GABA~A~R subtypes at EC~10~ of GABA. Data are mean ± SEM. Curves represent fits to the Hill equation with a baseline fixed to 0. n, numbers of cells, 5--7 for all data points.](gr1){#fig1}

![Antihyperalgesic actions of NDMC. Reversal of mechanical hyperalgesia (A,C,E; assessed with von Frey filaments) and thermal hyperalgesia (B,D,F; assessed in the Hargreaves test) by NDMC 7--14 days after CCI surgery in wild-type C57BL/6J (A,B), wild-type 129X1/SvJ (C,D) and quadruple (H → R) 129X1/SvJ point-mutated mice (E,F). Left panels, paw withdrawal threshold or latencies (mean ± SEM) versus time after drug application. Horizontal lines indicates time interval used for the statistical analyses. Right panels, statistical analysis. Black circles, individual mice; blue lines mean ± SEM. (A--D): \*\*\**P* \< 0.001, \*\**P* \< 0.01, \**P* \< 0.05 significant versus vehicle-treated mice (ANOVA followed by Dunnett's post hoc test); (A) F(3,41) = 19.8, n = 10, 12, 11, 11 for vehicle and 3, 10 and 30 mg kg^−1^ NDMC, respectively; (B) F(3,49) = 15.2, n = 14, 13, 13, 12 for vehicle and 3, 10 and 30 mg kg^−1^ NDMC; (C) F(3,21) = 16, n = 6, 6, 7 and 6 mice, for vehicle and 3, 10 and 30 mg kg^−1^ NDMC; (D): F(3,20) = 9.8, n = 6, 6, 6 and 6 mice, for vehicle and 3, 10 and 30 mg kg^−1^ NDMC; (E) unpaired *t*-test, n = 9 and 8 for wild-type and quadruple point-mutated mice, respectively; (F) unpaired *t*-test, n = 4 for both groups of mice. NDMC dose in panels E and F was 30 mg kg^−1^.](gr2){#fig2}

![Locomotor sedation by DZP and NDMC. Effects of orally applied DZP (A,C), and NDMC (B,D) in C57BL/6J (A,B) and 129X1/SvJ mice (C,D) on locomotor activity in the open field test. Left panels, number of light beam crosses (mean ± SEM) versus time after drug application. Horizontal lines indicates time interval used for the statistical analyses. Right panels, statistical analyses, performed for the interval 72--120 min. \*\*\**P* \< 0.001; \*\**P* \< 0.01; \**P* \< 0.05 significant versus vehicle-treated mice (ANOVA followed by Dunnett's post hoc test. (A) F(4,28) = 9.2, n = 7, 7, 6, 6 and 7 for vehicle and DZP 1, 3, 10 and 30 mg kg^−1^, respectively. (B) F(3,19) = 3.2, n = 6, 6, 5 and 6 for vehicle and NDMC 3, 10 and 30 mg kg^−1^. (C) F(3,24) = 5.85, n = 8, 6, 8, 6 for vehicle and DZP 3, 10 and 30 mg kg^−1^. (D) *P* \> 0.87, F(3,22) = 0.31, n = 7, 6, 7 and 6, for vehicle and NDMC 3, 10 and 30 mg kg^−1^.](gr3){#fig3}

![Opposing effects of α1 and α2GABA~A~R activation on locomotor activity. Effects of oral DZP (A,C,E), and NDMC (B,D,F) on locomotor activity in the open field test in mice carrying the H → R point mutation in multiple GABA~A~R subtypes (α2, α3, and α5, in (A,B) or α1, α3, and α5 in (C,D)) leaving only α1GABA~A~Rs (A,B) or α2GABA~A~Rs (B,D) BDZ-sensitive. (E,F) Same experiments as (A,B) but performed in quadruple point-mutated mice, in which all four subtypes (α1, α2, α3, and α5) of DZP sensitive GABA~A~Rs have been rendered insensitive. Left panels, number of light beam crosses (mean ± SEM) versus time after drug application. Horizontal lines indicates time interval used for the statistical analyses. Right panels, statistical analyses, performed for the interval 72--120 min. \*\*\**P* \< 0.001; \*\**P* \< 0.01; \**P* \< 0.05 significant versus vehicle-treated mice (ANOVA followed by Dunnett's post hoc test. (A) F(5,29) = 35.7, n = 6, 6, 8, 5, 5 and 5 for vehicle and 0.3, 1, 3, 10 and 30 mg kg^−1^, respectively); (B) F(4,25) = 13.2, n = 10, 5, 5, 5 and 5 for vehicle and 1, 3, 10 and 30 mg kg^−1^. (C) (5,25) = 13.2, n = 5, 6, 2, 6, 6 and 6 for vehicle and 0.3, 1, 3, 10 and 30 mg kg^−1^. (D) F(4,22) = 4.6 (n = 6, 6, 5, 5 and 5 for vehicle and 3, 10, 30 and 100 mg kg^−1^. (E) F(3,16) = 4.9, n = 5, 5, 5 and 5 for vehicle and 10, 30 and 100 mg kg^−1^. (F) F(3,23) = 1.3, n = 7, 6, 6 and 8 for vehicle and 30, 100 and 300 mg kg^−1^.](gr4){#fig4}

![Pharmacokinetics of NDMC in mice. (A) Whole blood NDMC concentrations measured over time after p.o. administration of 3, 10 or 30 mg kg^−1^ NDMC (green, blue, red lines) to three (C57BL/6) mice per dose. Lines are fits to the Bateman function. (B) Whole blood (black) and brain tissue (red) concentrations determined at 2 h after p.o. administration of NDMC (0.3, 3, 10, 30, and 100 mg kg^−1^). Data points represent measurements taken from individual (129X1/SvJ) mice. Brain tissue concentrations in ng mg^−1^ were converted into micromolar concentrations assuming a specific mass of brain tissue of 1 g ml^−1^.](gr5){#fig5}

![Therapeutic windows of DZP and NDMC. α1GABA~A~R-mediated sedation and α2GABA~A~R-mediated antihyperalgesia by DZP (A) and NDMC (B,C). (A) Sedation in α2/α3/α5(H → R) triple point mutated mice: n = 6, 6, 8, 5 and 5 for vehicle and DZP 0.3, 1, 3, 10 and 30 mg kg^−1^, respectively; antihyperalgesia in α1(H → R) single point-mutated mice: n = 20, 7, 14, 13 and 6, for vehicle and DZP 1, 3, 10 and 30 mg kg^−1^, respectively. (B) Sedation in α2/α3/α5 (H → R) triple point-mutated mice: n = 10, 5, 5, 5, 5 and 4 for vehicle and NDMC 1, 3, 10, 30 and 100 mg kg^−1^, respectively. Antihyperalgesia in α1(H → R) single point-mutated mice: n = 6, 6, 6, 5 and 5 mice, for vehicle and NDMC 1, 3, 10 and 30 mg kg^−1^, respectively. Data points are mean ± SEM. (C) Same as (B) but antihyperalgesia and sedation plotted versus whole blood concentrations and estimated CSF concentrations (for details of conversion see [Discussion](#sec4){ref-type="sec"}).](gr6){#fig6}

###### 

Binding affinities and electrophysiological properties of DZP, CBZ and NDMC at recombinant GABA~A~Rs expressed in HEK203 cells.

           DZP             CBZ             NDMC                                                                                                                  
  -------- --------------- --------------- ----------- ------------- ------------- ------------- ---------- ------------- ------------- ------------- ---------- -------------
  α1β2γ2   0.019 ± 0.005   0.033 ± 0.016   141 ± 17                  0.43 ± 0.13   0.61 ± 0.20   171 ± 17                 0.78 ± 0.15   0.57 ± 0.18   143 ± 13   
  α2β3γ2   0.017 ± 0.004   0.048 ± 0.012   123 ± 11    0.88 ± 0.13   0.39 ± 0.08   0.39 ± 0.19   134 ± 16   0.78 ± 0.12   0.59 ± 0.12   0.49 ± 0.24   253 ± 32   1.77 ± 0.28
  α3β3γ2   ND              0.071 ± 0.013   227 ± 15                  ND            1.10 ± 0.32   317 ± 30                 ND            0.81 ± 0.30   245 ± 29   
  α5β3γ2   ND              0.029 ± 0.006   100 ± 6.4                 ND            0.50 ± 0.12   157 ± 11                 ND            0.58 ± 0.18   148 ± 15   

ND, not determined.

Data are means ± SD.

Determined as E~max~(α2)/E~max~(α1).

###### 

Pharmacokinetics of NDMC in mice after p.o. administration.

  Dose (mg/kg)   Half-life (h)   C~max~ (μg/ml)   AUC (h\*μg/ml)   T~max~ (h)
  -------------- --------------- ---------------- ---------------- ------------
  3              5.6 ± 0.6       1.19 ± 2.53      11.15 ± 1.66     2.0 ± 0.9
  10             4.6 ± 1.6       1.91 ± 1.34      14.72 ± 4.38     3.0 ± 0.0
  30             4.7 ± 0.3       3.31 ± 1.01      32.28 ± 5.09     2.7 ± 0.6

Data are means ± SD, n = 3 per group.

[^1]: Shared first-authorship.

[^2]: Shared last-authorship.
